<DOC>
	<DOCNO>NCT02527772</DOCNO>
	<brief_summary>The purpose study determine Liposomal Doxorubicin ( LD ) plus Gemcitabine ( GEM ) superior Oxaliplatin（OXA） Plus Fluorouracil/Leucovorin ( FOLFOX4 ) prolong progression-free survival（PFS） patient Advanced Hepatocellular Carcinoma .</brief_summary>
	<brief_title>Liposomal Doxorubicin Plus Gemcitabine Versus Oxaliplatin Plus Fluorouracil/Leucovorin Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Eligible patient age 18 75 year ; The patient histologically , cytologically , clinically diagnose unresectable HCC ; ineligible local invasive treatment . Clinically diagnose patient : ( 1 ) evidence HBV HCV hepatic cirrhosis ; ( 2 ) afetoprotein level 400g/L ; ( 3 ) morphologic evidence hypervascular liver tumor . Patients least one measurable lesion accord RECIST ( version 1.0 ; ≥2 cm compute tomography [ CT ] ; 1 cm spiral CT magnetic resonance imaging ) . Lesions undergone previous interventional local therapy consider measurable lesion . ECOG score≤2 ; life expectancy 3 month ; Barcelona Clinic liver cancer ( BCLC ) stage B C disease ; ChildPugh stage A B disease ; Adequate organ marrow function , neutrophil count≥1.5X10e9/L , platelet count≥75×10e9/L , AST ALT﹤2.5×upper limit normal ( ULN ) , total bilirubin ＜1.5×ULN , international normalize ratio ＜1.5 ; normal baseline leave ventricular ejection fraction_lower limit normal institution . Patients AST ALT＜ 5 ×ULN could recruit total bilirubin normal range . Patients provide sign informed consent participate . document allergy platinum compound study drug ; previous OXA DOX treatment , except adjuvant treatment ﹥12 month random assignment ; Previous liver transplantation ; concomitant use anticancer therapy , include interferon alfa herbal medicine approve local authority use anticancer medicine ( except palliative radiotherapy nontarget lesion ) ; CNS metastasis ; Other serious illness medical condition .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>